Design, synthesis, and biological evaluation of naphthalene imidazo[1,2‐ b ]pyridazine hybrid derivatives as VEGFR selective inhibitors
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400411 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Shuang Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, College of Pharmacy, Chongqing Medical University, Chongqing, People's Republic of China. Hauptthemen laut MEDLINE: Pyridazines, Naphthalenes, Drug Design, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Chongqing Doctoral "Through Train" Scientific Research Program.
Abstract (Originalsprache)
The vascular endothelial growth factor receptor (VEGFR) is a receptor tyrosine kinase that is regarded as an emerging target for abnormal angiogenesis diseases. In this study, novel naphthalene imidazo[1,2‐ b ]pyridazine hybrids as VEGFR selective inhibitors were designed and synthesized using a scaffold hopping strategy based on ponatinib, a multitarget kinase inhibitor. Among the evaluated compounds, derivative 9k (WS‐011) demonstrated the most potent inhibitory potency against VEGFR‐2 (IC 50 = 8.4 nM) and displayed superior VEGFR selectivity over a panel of 70 kinases compared with ponatinib. Furthermore, 9k possessed good cytotoxic effects on various cancer cell lines, especially the colon cancer HT‐29 cells, with an acceptable oral bioavailability. Moreover, 9k significantly inhibited the migration and invasion of human umbilical vein endothelial cells (HUVEC) cells and induced apoptosis through the upregulation of apoptotic proteins in HT‐29 cells. 9k also effectively suppressed the activation of VEGFR‐2 signaling pathways, which in turn inhibited the growth of HT‐29 cells and the tube formation of HUVECs in vitro. All of the findings revealed that 9k could be considered a promising antiangiogenesis lead that merits further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, College of Pharmacy, Chongqing Medical University, Chongqing, People's Republic of China.
- Chongqing Engineering Research Center of Pharmaceutical Sciences, School of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing, People's Republic of China.
- Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Chongqing Doctoral "Through Train" Scientific Research Program
- CQMU Program for Youth Innovation in Future Medicine
Zitieren
APA
Wang, S., Gan, L., Han, L., Deng, P., Li, Y., He, D., Chi, H., Zhu, L., Li, Y., Long, R., & Gan, Z. (2024). Design, synthesis, and biological evaluation of naphthalene imidazo[1,2‐ b ]pyridazine hybrid derivatives as VEGFR selective inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400411
Vancouver
Wang S, Gan L, Han L, Deng P, Li Y, He D, et al. Design, synthesis, and biological evaluation of naphthalene imidazo[1,2‐ b ]pyridazine hybrid derivatives as VEGFR selective inhibitors. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400411
BibTeX
@article{Wang2024,
author = {Wang, Shuang and Gan, LinLing and Han, Lei and Deng, Ping and Li, Yihao and He, Dongxiao and Chi, Haoze and Zhu, Liwei and Li, Yuehui and Long, Rui and Gan, Zongjie},
title = {Design, synthesis, and biological evaluation of naphthalene imidazo[1,2‐ b ]pyridazine hybrid derivatives as VEGFR selective inhibitors},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400411}
}
EUVIMED